Diagnostic Biomarkers Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Demand for Early Diagnosis
- Advancement in Diagnostic Technology
Challenges
- High Cost of Diagnostic Biomarkers
Diagnostic Biomarkers Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
11.7% |
|
Base Year Market Size (2024) |
USD 62.43 billion |
|
Forecast Year Market Size (2037) |
USD 263.08 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of diagnostic biomarkers is assessed at USD 68.64 billion.
Diagnostic Biomarkers Market size was over USD 62.43 billion in 2024 and is projected to reach USD 263.08 billion by 2037, witnessing around 11.7% CAGR during the forecast period i.e., between 2025-2037.
North America industry is likely to account for largest revenue share by 2037, impelled by efficient healthcare sector, supported by high government investment.
The major players in the market are PerkinElmer Inc., Biomarker Technologies, Inc., Almac Group Limited, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Epigenomics AG, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN GmbH and others.
